Psychotropic Drug Directory supports the optimal and rational use of medicines, to improve the quality of life for people with mental health needs.
Close
Close
Contact our team to see how our services can directly help you.
Close
Access our useful resources today to help your organisation realise the benefits of subscribing to Psychotropic Drug Directory through MedicinesComplete. Including patient case studies covering everyday clinical scenarios, and an on-demand webinar showing how to navigate independent information, advice, and commentary on psychotropic drugs.
Close
Register for this webinar to learn how MedicinesComplete can support you in implementing effective processes to reduce medication errors and improve patient safety.
Close
Learn more about adverse drug reactions in our article.
Close
This update contains 2 new monographs and 16 revised monographs.
New monographs: Ganaxolone; Vutrisiran
Revised monographs: Alectinib; Bosutinib; Cabozantinib; Decitabine and Cedazuridine, Erdafitinib, Inotersen, Lanreotide; Lemborexant; Osimertinib; Patisiran; romiPLOStim; Ruxolitinib; Sarilumab; SORAfenib; Suvorexant; Tecovirimat.
